M-N VAN THIENEN
Department of Medical Genetics, University of
Antwerp, Belgium

K KEYMOLEN
Centre for Medical Genetics, University of Brussels,
Belgium

- 1 Scambler PJ, Kelly D, Lindsay E, *et al.* Velocardio-facial syndrome associated with chromosome 22 deletions encompassing the Di-George locus. *Lancet* 1992;339:1138-9.
- 2 Driscoll DA, Salvin J, Sellinger B, *et al.* Prevalence of 22q11 microdeletions in Di-George and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis. *J Med Genet* 1993;30:813-17.
- 3 Wilson DI, Cross IE, Wren C, *et al.* Minimum prevalence of chromosome 22q11 deletions. *Am J Hum Genet* 1994;55:A169.
- 4 Du Montcel ST, Mendizabal H, Aymé S, Lévy A, Philip N. Prevalence of 22q11 microdeletion. *J Med Genet* 1996;33:719.

Sharing of PPT mutations between distinct clinical forms of neuronal ceroid lipofuscinoses in patients from Scotland

The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of rare inherited neurodegenerative diseases of childhood classified according to their age of onset and ultrastructural appearance of storage material. A very unusual cluster of NCL cases is found in the west of Scotland.¹ Some patients have early infantile onset, INCL, a disease almost entirely confined to Finland and characterised on ultrastructure by granular osmiophilic deposits (GROD). Other patients have a later, juvenile, onset but are found to have GROD (vJNCL/GROD) rather than the fingerprint profiles usually found in juvenile onset cases. INCL in Finland is caused by mutations in the gene encoding palmitoyl protein thioesterase, PPT.² It was recently reported that cases of vJNCL/GROD from Scotland (and elsewhere) also result from mutations in this gene.³ We set out to determine the disease causing mutations in PPT in Scottish INCL patients to establish whether there was any sharing of mutations with vJNCL/GROD.

Four patients with a diagnosis of INCL were analysed. Exons of PPT were amplified from genomic DNA by PCR and then sequenced in forward and reverse directions.³ We found mutations in PPT in all four patients and of the eight chromosomes analysed three different nonsense mutations (Leu10STOP, Lys55STOP, and Arg151STOP, table 1) were present. Therefore, all the INCL patients are homozygous for mutations predicted to result in truncation of PPT. For each patient we amplified parental DNA and were able to show Mendelian inheritance of mutations.

Two of these mutations (Leu10STOP and Arg151STOP) are found in patients with vJNCL/GROD.³ However, in these cases

nonsense mutations do not occur in homozygous form and are only found in combination with a missense mutation. Therefore, we can now show that two clinically distinct forms of NCL are caused by shared mutations in PPT. The clinical significance of these findings is that the severity of the disease in these patients is dependent on the combination and type of mutations present.

There are several diseases in which different mutations in the same gene cause dissimilar clinical phenotypes, for example, CFTR (cystic fibrosis and congenital bilateral absence of the vas deferens⁴). Types A and B Niemann-Pick disease, like the NCLs, are lysosomal storage disorders which are both caused by mutations in the acid sphingomyelinase gene. As in this study, the same mutation has been found in both forms and the age of onset and severity of the phenotype is dependent on the other allele.⁵

Geographical clustering of a rare autosomal recessive genetic disease suggests a founder effect with patients inheriting the same ancestral disease chromosomes. Detailed genealogical information is not available on these patients. However, all but one of the 18 disease chromosomes in INCL and vJNCL/GROD cases are accounted for by two nonsense and one missense mutations (table 1) and it is likely that these are derived from individual ancestral chromosomes. High resolution haplotype analysis and population studies to determine carrier rates will be required to resolve the issue.

We thank the Medical Research Council (PBM, NDEG) and Action Research (KYL) for financial support.

PATRICIA B MUNROE
NICHOLAS D E GREENE
KIT-YI LEUNG
SARA E MOLE
R MARK GARDINER
HANNAH M MITCHISON

Department of Paediatrics, University College London
Medical School, Rayne Institute, 5 University Street,
London WC1E 6JJ, UK

JOHN B P STEPHENSON
YANICK J CROW

Departments of Paediatric Neurology and Medical
Genetics, Yorkhill Hospitals NHS Trust,
Glasgow G3 8SJ, UK

- 1 Crow YJ, Tolmie JL, Howatson AG, Patrick WJA, Stephenson JBP. Batten disease in the West of Scotland 1974-1995 including five cases of the juvenile form with granular osmiophilic deposits. *Neuropediatrics* 1997;28:140-4.
- 2 Vesa J, Hellsten E, Verkruyse LA, *et al.* Mutations in the palmitoyl-protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. *Nature* 1995;376:584-7.
- 3 Mitchison HM, Hofmann SL, Becerra CHR, *et al.* Mutations in palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits. *Hum Mol Genet* 1998;7:291-7.
- 4 Chillon M, Casals I, Mercier B, *et al.* Mutations in the cystic-fibrosis gene in patients with congenital absence of the vas-deferens. *N Engl J Med* 1995;332:1475-80.

- 5 Levran O, Desnick RJ, Schuchman EH. Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. *J Clin Invest* 1991;88:806-10.

PTEN and prostate cancer

The PTEN gene (phosphate and tensin homologue), located on 10q23,^{1,2} has been reported to be the Cowden disease susceptibility gene. Germline mutations in PTEN have been found in patients with this syndrome.³ This disorder is characterised by the development of hamartomas at various sites, as well as an increased predisposition for thyroid cancer and for breast cancer in women.⁴⁻⁶ PTEN has also been reported as being altered in other types of cancer including glioblastoma,^{1,2} endometrial carcinoma,^{7,8} and kidney carcinoma.² This gene has additionally been suggested to play a role in prostate cancer as PTEN alterations have been found in multiple prostate cancer cell lines.¹

In order to investigate the role of mutations in the PTEN gene in primary prostate cancer, we analysed microdissected prostate adenocarcinoma tissue from 28 patients with histopathologically confirmed cancer. All nine exons of PTEN were PCR amplified and screened for mutations by single strand conformational polymorphism analysis (SSCP). Samples displaying mobility shifts were subjected to DNA sequence analysis. This analysis failed to detect homozygous deletions of the PTEN gene in any sample. A heterozygous mutation was identified in only one of the prostate tumour samples and was characterised as a single base deletion in codon 68 (TAC→AC). Additionally, an A→G polymorphism 96 bp upstream of the beginning of exon 2 was found in nine of 28 samples (32.1%). Based on this analysis, we conclude that mutations of the PTEN gene are rare in primary prostate cancers.

EVAN A FACHER

Department of Epidemiology and Biostatistics, Case
Western Reserve University, 2500 MetroHealth Drive,
Rammelkamp-R459, Cleveland, OH 44109, USA

JOHN C LAW

Department of Human Genetics, University of
Pittsburgh, USA

- 1 Li J, Yen C, Liaw D, *et al.* PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 1997;275:1943-7.
- 2 Steck PA, Pershouse MA, Jasser SA, *et al.* Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 1997;15:356-62.
- 3 Liaw D, Marsh DJ, Li J, *et al.* Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* 1997;16:64-7.
- 4 Carlson HE, Burns TW, Davenport SL, *et al.* Cowden disease: gene marker studies and measurements of epidermal growth factor. *Am J Hum Genet* 1986;38:908-17.
- 5 Starink TM, van der Veen JP, Arwert F, *et al.* The Cowden syndrome: a clinical and genetic study in 21 patients. *Clin Genet* 1986;29:222-33.
- 6 Eng C, Murday V, Seal S, *et al.* Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? *J Med Genet* 1994;31:458-61.
- 7 Kong D, Suzuki A, Zou TT, *et al.* PTEN1 is frequently mutated in primary endometrial carcinomas. *Nat Genet* 1997;17:143-4.
- 8 Tashiro H, Blazes MS, Wu R, *et al.* Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. *Cancer Res* 1997;57:3935-40.

Table 1 PPT mutations in Scottish INCL and vJNCL/GROD

Case	Disease	Mutations
389	INCL	Arg151STOP/Arg151STOP
390	INCL	Arg151STOP/Lys55STOP
392	INCL	Arg151STOP/Leu10STOP
391	INCL	Leu10STOP/Leu10STOP
105, 341, 346	vJNCL/GROD ³	Arg151STOP/Thr75Pro
325, 345	vJNCL/GROD ³	Leu10STOP/Thr75Pro

Bold type indicates mutations present in both INCL and vJNCL/GROD.